Does the media prefer CELU or VRCA?

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.72 indicating that Celularity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PYXS or CELU?

In the previous week, Pyxis Oncology and Pyxis Oncology both had 2 articles in the media. Pyxis Oncology's average media sentiment score of 0.94 beat Celularity's score of 0.93 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celularity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BMEA or CELU more profitable?

Biomea Fusion has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -265.37% -103.96% Celularity -345.45% N/A -77.94%

Does the media refer more to BMEA or CELU?

In the previous week, Biomea Fusion and Biomea Fusion both had 2 articles in the media. Celularity's average media sentiment score of 0.93 beat Biomea Fusion's score of 0.62 indicating that Celularity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celularity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CELU or ONCY?

In the previous week, Oncolytics Biotech had 14 more articles in the media than Celularity. MarketBeat recorded 16 mentions for Oncolytics Biotech and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Oncolytics Biotech's score of -0.57 indicating that Celularity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend ICCC or CELU?

Celularity has a consensus target price of $6.00, suggesting a potential upside of 476.92%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, ICCC or CELU?

ImmuCell has higher revenue and earnings than Celularity. ImmuCell is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $27.64M 3.14 -$1.04M -$0.06 N/A Celularity $26.55M 1.13 -$91.72M -$3.33 N/A

Is ICCC or CELU more profitable?

ImmuCell has a net margin of -1.82% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat ImmuCell's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell -1.82% -1.88% -1.22% Celularity -345.45% N/A -77.94%

Celularity (CELU) Competitors

$1.04 +0.03 (+2.97%)

As of 01:05 PM Eastern

Compare

CELU vs. VRCA, PYXS, BMEA, ONCY, and ICCC

Should you buy Celularity stock or one of its competitors? MarketBeat compares Celularity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Celularity include Verrica Pharmaceuticals (VRCA), Pyxis Oncology (PYXS), Biomea Fusion (BMEA), Oncolytics Biotech (ONCY), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry.

How does Celularity compare to Verrica Pharmaceuticals?

Celularity (NASDAQ:CELU) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Celularity currently has a consensus target price of $6.00, indicating a potential upside of 476.92%. Verrica Pharmaceuticals has a consensus target price of $14.50, indicating a potential upside of 140.66%. Given Celularity's higher possible upside, research analysts plainly believe Celularity is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Verrica Pharmaceuticals has a net margin of -47.97% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

19.0% of Celularity shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Celularity has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

Verrica Pharmaceuticals has higher revenue and earnings than Celularity. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.13	-$91.72M	-$3.33	N/A
Verrica Pharmaceuticals	$37.16M	2.79	-$17.89M	-$1.03	N/A

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Verrica Pharmaceuticals' score of 0.72 indicating that Celularity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Verrica Pharmaceuticals beats Celularity on 12 of the 16 factors compared between the two stocks.

How does Celularity compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Pyxis Oncology currently has a consensus price target of $6.83, indicating a potential upside of 298.45%. Celularity has a consensus price target of $6.00, indicating a potential upside of 476.92%. Given Celularity's higher possible upside, analysts plainly believe Celularity is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Pyxis Oncology and Pyxis Oncology both had 2 articles in the media. Pyxis Oncology's average media sentiment score of 0.94 beat Celularity's score of 0.93 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Celularity has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market.

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 10.6% of Pyxis Oncology shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pyxis Oncology has higher earnings, but lower revenue than Celularity. Pyxis Oncology is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	7.84	-$79.62M	-$1.31	N/A
Celularity	$26.55M	1.13	-$91.72M	-$3.33	N/A

Pyxis Oncology has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Celularity	-345.45%	N/A	-77.94%

Summary

Pyxis Oncology beats Celularity on 9 of the 15 factors compared between the two stocks.

How does Celularity compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Biomea Fusion has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Celularity	-345.45%	N/A	-77.94%

Biomea Fusion currently has a consensus target price of $8.29, suggesting a potential upside of 489.73%. Celularity has a consensus target price of $6.00, suggesting a potential upside of 476.92%. Given Biomea Fusion's stronger consensus rating and higher possible upside, research analysts plainly believe Biomea Fusion is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biomea Fusion has higher earnings, but lower revenue than Celularity. Biomea Fusion is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Celularity	$26.55M	1.13	-$91.72M	-$3.33	N/A

In the previous week, Biomea Fusion and Biomea Fusion both had 2 articles in the media. Celularity's average media sentiment score of 0.93 beat Biomea Fusion's score of 0.62 indicating that Celularity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biomea Fusion has a beta of -0.31, meaning that its share price is 131% less volatile than the broader market. Comparatively, Celularity has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by insiders. Comparatively, 17.3% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Biomea Fusion and Celularity tied by winning 7 of the 14 factors compared between the two stocks.

How does Celularity compare to Oncolytics Biotech?

Celularity (NASDAQ:CELU) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, Oncolytics Biotech had 14 more articles in the media than Celularity. MarketBeat recorded 16 mentions for Oncolytics Biotech and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Oncolytics Biotech's score of -0.57 indicating that Celularity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oncolytics Biotech	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Celularity currently has a consensus price target of $6.00, suggesting a potential upside of 476.92%. Oncolytics Biotech has a consensus price target of $8.50, suggesting a potential upside of 779.92%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

19.0% of Celularity shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Celularity has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

Oncolytics Biotech has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

Oncolytics Biotech has lower revenue, but higher earnings than Celularity. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.13	-$91.72M	-$3.33	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

Summary

Oncolytics Biotech beats Celularity on 9 of the 16 factors compared between the two stocks.

How does Celularity compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

In the previous week, ImmuCell and ImmuCell both had 2 articles in the media. ImmuCell's average media sentiment score of 1.30 beat Celularity's score of 0.93 indicating that ImmuCell is being referred to more favorably in the media.

Company	Overall Sentiment
ImmuCell	Positive
Celularity	Positive

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 17.3% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Celularity has a consensus target price of $6.00, suggesting a potential upside of 476.92%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ImmuCell has higher revenue and earnings than Celularity. ImmuCell is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.14	-$1.04M	-$0.06	N/A
Celularity	$26.55M	1.13	-$91.72M	-$3.33	N/A

ImmuCell has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Celularity has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

ImmuCell has a net margin of -1.82% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Celularity	-345.45%	N/A	-77.94%

Summary

ImmuCell beats Celularity on 8 of the 15 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELU vs. The Competition

Export

Metric	Celularity	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$29.24M	$3.37B	$6.39B	$12.60B
Dividend Yield	N/A	2.29%	2.69%	5.30%
P/E Ratio	-0.31	18.01	21.14	26.64
Price / Sales	1.13	182.95	513.05	95.52
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	-0.79	6.53	9.81	6.79
Net Income	-$91.72M	$24.15M	$3.56B	$337.23M
7 Day Performance	15.95%	-1.39%	0.40%	2.67%
1 Month Performance	8.67%	1.04%	4.87%	6.66%
1 Year Performance	-53.57%	51.35%	31.14%	37.99%

Celularity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELU Celularity	2.0203 of 5 stars	$1.04 +3.0%	$6.00 +476.9%	-51.1%	$29.24M	$26.55M	N/A	220
VRCA Verrica Pharmaceuticals	2.9997 of 5 stars	$6.02 -0.7%	$14.50 +140.9%	+17.8%	$103.42M	$35.58M	N/A	40	Analyst Downgrade
PYXS Pyxis Oncology	3.853 of 5 stars	$1.63 -16.8%	$6.83 +319.2%	+47.9%	$103.26M	$13.86M	N/A	60	Gap Up
BMEA Biomea Fusion	2.0151 of 5 stars	$1.41 -0.7%	$8.29 +487.6%	-3.5%	$101.94M	N/A	N/A	50	Analyst Downgrade
ONCY Oncolytics Biotech	3.5739 of 5 stars	$0.81 +0.1%	$8.50 +949.0%	+199.8%	$96.71M	N/A	N/A	30	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELU) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celularity (CELU) Competitors

CELU vs. VRCA, PYXS, BMEA, ONCY, and ICCC

How does Celularity compare to Verrica Pharmaceuticals?

Summary

How does Celularity compare to Pyxis Oncology?

Summary

How does Celularity compare to Biomea Fusion?

Summary

How does Celularity compare to Oncolytics Biotech?

Summary

How does Celularity compare to ImmuCell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celularity (CELU) Competitors

CELU vs. VRCA, PYXS, BMEA, ONCY, and ICCC

How does Celularity compare to Verrica Pharmaceuticals?

Do analysts prefer CELU or VRCA?

Is CELU or VRCA more profitable?

Do insiders & institutionals hold more shares of CELU or VRCA?

Which has more volatility and risk, CELU or VRCA?

Which has preferable valuation and earnings, CELU or VRCA?

Does the media prefer CELU or VRCA?

Summary

How does Celularity compare to Pyxis Oncology?

Do analysts recommend PYXS or CELU?

Does the media prefer PYXS or CELU?

Which has more risk and volatility, PYXS or CELU?

Do insiders and institutionals hold more shares of PYXS or CELU?

Which has preferable valuation & earnings, PYXS or CELU?

Is PYXS or CELU more profitable?

Summary

How does Celularity compare to Biomea Fusion?

Is BMEA or CELU more profitable?

Do analysts rate BMEA or CELU?

Which has preferable earnings & valuation, BMEA or CELU?

Does the media refer more to BMEA or CELU?

Which has more risk and volatility, BMEA or CELU?

Do insiders & institutionals hold more shares of BMEA or CELU?

Summary

How does Celularity compare to Oncolytics Biotech?

Does the media favor CELU or ONCY?

Do analysts rate CELU or ONCY?

Do insiders and institutionals have more ownership in CELU or ONCY?

Which has more risk & volatility, CELU or ONCY?

Is CELU or ONCY more profitable?

Which has preferable valuation & earnings, CELU or ONCY?

Summary

How does Celularity compare to ImmuCell?

Does the media refer more to ICCC or CELU?

Do institutionals & insiders have more ownership in ICCC or CELU?

Do analysts recommend ICCC or CELU?

Which has better earnings & valuation, ICCC or CELU?

Which has more volatility and risk, ICCC or CELU?

Is ICCC or CELU more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools